Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McDonnell

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Neuropsychiatric Disease and Treatment|October 1, 2019
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and futureLeslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, et al.
The Journal of Clinical Psychiatry|April 7, 2026
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With SchizophreniaRoger S McIntyre, Desiree M Matthews, Christina Arevalo, et al.
The Journal of Clinical Psychiatry|May 3, 2008
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJohn Lauriello, Tim Lambert, Scott Andersen, et al.
CNS Spectrums|October 13, 2022
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patientsJonathan M Meyer, Adam Simmons, Ying Jiang, et al.
The Journal of Clinical Psychiatry|January 20, 2025
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind StudiesChristoph U Correll, Michael J Doane, David McDonnell, et al.
Neuropsychiatric Disease and Treatment|July 15, 2014
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionHaya Ascher-Svanum, Diego Novick, Josep Maria Haro, et al.
BMC Psychiatry|September 18, 2013
Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyHaya Ascher-Svanum, Diego Novick, Josep Maria Haro, et al.
The International Journal of Neuropsychopharmacology|June 16, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-AnalysisChristoph U Correll, Mikkel Højlund, Christine Graham, et al.
Frontiers in Psychiatry|September 5, 2024
Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patientsAdam Simmons, Amy K O'Sullivan, Julia Carpenter-Conlin, et al.
The Mental Health Clinician|October 20, 2023
Comment on "Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review"Mark S Todtenkopf, Christoph U Correll, Marni E Harris-White, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Neuropsychiatric Disease and Treatment|October 1, 2019
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and futureLeslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, et al.
The Journal of Clinical Psychiatry|April 7, 2026
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With SchizophreniaRoger S McIntyre, Desiree M Matthews, Christina Arevalo, et al.
The Journal of Clinical Psychiatry|May 3, 2008
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJohn Lauriello, Tim Lambert, Scott Andersen, et al.
CNS Spectrums|October 13, 2022
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patientsJonathan M Meyer, Adam Simmons, Ying Jiang, et al.
The Journal of Clinical Psychiatry|January 20, 2025
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind StudiesChristoph U Correll, Michael J Doane, David McDonnell, et al.
Neuropsychiatric Disease and Treatment|July 15, 2014
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionHaya Ascher-Svanum, Diego Novick, Josep Maria Haro, et al.
BMC Psychiatry|September 18, 2013
Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyHaya Ascher-Svanum, Diego Novick, Josep Maria Haro, et al.
The International Journal of Neuropsychopharmacology|June 16, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-AnalysisChristoph U Correll, Mikkel Højlund, Christine Graham, et al.
Frontiers in Psychiatry|September 5, 2024
Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patientsAdam Simmons, Amy K O'Sullivan, Julia Carpenter-Conlin, et al.
The Mental Health Clinician|October 20, 2023
Comment on "Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review"Mark S Todtenkopf, Christoph U Correll, Marni E Harris-White, et al.
Pageof 4